Ranok Therapeutics is developing targeted protein degradation (TPD) technology to create safer and more effective cancer therapies by selectively eliminating disease-causing proteins. This approach addresses the limitations of traditional therapies by targeting well-validated and novel drug targets implicated in cancer and other diseases with significant unmet medical needs.
Funding
$40M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
LCSHFounders
Product
Problem
Traditional cancer therapies often suffer from limitations in efficacy and safety due to their inability to selectively target and eliminate disease-causing proteins. Many well-validated and novel drug targets implicated in cancer and other diseases remain unaddressed, resulting in significant unmet medical needs.
Solution
Ranok Therapeutics is developing targeted protein degradation (TPD) therapeutics using its proprietary Chaperone-Mediated Protein Degradation (CHAMP™) technology. This next-generation TPD approach selectively eliminates disease-causing proteins by harnessing the chaperone-mediated pathway and the ubiquitin-proteasome system (UPS). By inducing the degradation of target proteins, Ranok's approach aims to downregulate the expression of genes regulated by these proteins, leading to safer and more effective cancer therapies. The CHAMP™ platform offers unique advantages over competing TPD approaches by engaging different underlying biological processes.
Target Audience
The primary target audience includes patients suffering from cancers and other diseases with significant unmet medical needs, as well as researchers and clinicians seeking more effective and safer therapeutic options.
Features
- CHAMP™ technology platform targeting the chaperone-mediated protein degradation pathway
- Selective degradation of target proteins via the ubiquitin-proteasome system (UPS)
- Downregulation of BRD4-regulated gene expression
- RNK05047: a novel, small-molecule, chaperone-mediated protein degrader (CHAMP) targeting BRD4 protein
- RNK08954: a novel, oral small-molecule, non-covalently inhibits KRAS (Kirsten rat sarcoma) G12D
- RNK08954 selectively binds to KRAS G12D over other mutations and wild type
- RNK08954 achieves high exposure in tumors for the treatment of advanced solid tumors with a specific KRAS Mutation